GCM
BMRN icon

Greenland Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Greenland Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.98M Buy
+35,000
New +$2.04M 0.25% 77

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Greenland Capital Management's BMRN Position: Q1 2026 in Review

Greenland Capital Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 18,100 shares worth $1.02M. The stake represents 0.13% of the portfolio and ranks #136 among its holdings. This is a return to the name: Greenland Capital Management previously reported a position in BMRN as recently as Q4 2024.

Greenland Capital Management first reported a position in BMRN in Q4 2024 and has held it in 2 quarters since. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Greenland Capital Management held 18,100 shares of BioMarin Pharmaceuticals worth $1.02M as of Q1 2026.
  • BioMarin Pharmaceuticals was a new Greenland Capital Management position in Q1 2026.
  • BioMarin Pharmaceuticals made up 0.13% of Greenland Capital Management's portfolio in Q1 2026, its #136 holding.
  • Greenland Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 2 quarters since.
  • 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Greenland Capital Management's 13F filing for Q1 2026, filed 15 May 2026.